Akari Therapeutics (AKTX) EBT (2014 - 2026)

Akari Therapeutics has disclosed EBT across 9 years of filings, most recently posting -$15.3 million for Q1 2026.

• EBT for Q1 2026 came in at -$15.3 million, down 313.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.2 million (down 74.5% YoY), and the FY2025 annual result was -$18.3 million, up 7.53% from the prior year.
• EBT came in at -$15.3 million for Q1 2026 at Akari Therapeutics, down from -$5.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$2.5 million in Q3 2023 to a low of -$15.3 million in Q1 2026.
• The 4-year median for EBT is -$4.6 million (2023), against an average of -$5.5 million.
• Across the five-year window, EBT soared 57.74% in 2025 and plunged 313.33% in 2026, its largest moves.
• Akari Therapeutics' EBT stood at -$5.1 million in 2023, then advanced by 25.79% to -$3.8 million in 2024, then slumped by 38.2% to -$5.2 million in 2025, then plunged by 193.77% to -$15.3 million in 2026.
• The last three EBT figures came in at -$15.3 million (Q1 2026), -$5.2 million (Q4 2025), and -$7.5 million (Q3 2025), per Business Quant data.